Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.
A deal for Prometheus could be announced as soon as Sunday, the people said, cautioning the talks could still fall apart.